Search

Your search keyword '"HARALD DARIUS"' showing total 265 results

Search Constraints

Start Over You searched for: Author "HARALD DARIUS" Remove constraint Author: "HARALD DARIUS" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
265 results on '"HARALD DARIUS"'

Search Results

1. Reducing rehospitalization in cardiac patients: a randomized, controlled trial of a cardiac care management program ('Cardiolotse') in Germany

2. Imaging Predictors of Left Ventricular Functional Recovery after Reperfusion Therapy of ST-Elevation Myocardial Infarction Assessed by Cardiac Magnetic Resonance

3. Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF

4. Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry

5. C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study

6. Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry

7. Is it Time to Transform Our Treatment Of Type 2 Diabetes

8. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

10. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide

11. 36-month clinical outcomes of patients with venous thromboembolism

12. Imaging Predictors of Left Ventricular Functional Recovery after Reperfusion Therapy of ST-Elevation Myocardial Infarction Assessed by Cardiac Magnetic Resonance

13. Diabetes und kardiovaskuläre Ereignisse

14. Empagliflozin in Patients with Chronic Kidney Disease

15. Duale Thrombozytenhemmung nach akutem Koronarsyndrom oder perkutaner Koronarintervention – womit und wie lange?

16. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.

17. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery

18. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention

19. Empfehlungen zur prähospitalen Behandlung des akuten Koronarsyndroms bei Patienten unter Dauertherapie mit neuen oralen Antikoagulanzien (NOAKs)

20. Vorhofflimmern und Antikoagulation im Alter

21. Antithrombotische Therapie bei akutem Koronarsyndrom und Vorhofflimmern

22. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin

23. The total amount of CRP within the first 72 h after STEMI is crucial for the outcome

24. [Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?]

25. Antithrombotische Therapie bei akutem Koronarsyndrom und Vorhofflimmern

26. [Prevention of venous thromboembolism in COVID-19 outpatients]

27. Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs

28. Improving care coordination for patients with cardiac disease: Study protocol of the randomised controlled new healthcare programme (Cardiolotse)

29. C-reactive protein increases myocardial damage after STEMI

30. C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study

31. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation]

32. Blutungen unter direkten oralen Antikoagulanzien

33. Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry

34. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial

35. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

36. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

37. Medikamentöse Thrombose-Prophylaxe bei ambulanten COVID-19-Patienten

38. The Changing Landscape for Stroke Prevention in AF

39. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention

40. Vorhofohrverschluss für Patienten mit Vorhofflimmern

41. 2230Results from the CAMI1 Study: selective CRP apheresis as a new treatment option in acute myocardial infarction

43. Procedural Success Rates and Mortality in Elderly Patients With Percutaneous Coronary Intervention for Cardiogenic Shock

44. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry

45. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients

46. Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights from the AUGUSTUS Trial

47. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

48. THE TOTAL AMOUNT OF CRP WITHIN THE FIRST 72 H AFTER STEMI IS CRUCIAL FOR THE OUTCOME

49. Konsensuspapier: Schlaganfallprophylaxe bei Patienten mit nichtvalvulärem Vorhofflimmern

50. Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. für 'Brustschmerz-Ambulanzen'

Catalog

Books, media, physical & digital resources